Investigational drugs for the treatment of cervical cancer

References

• Torre LA, American Cancer Society Epidemiologist SaHSRAG, Bray F, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2016;65:87–108.
   Web of Science ®Google Scholar
• Pimple S, Mishra G, Shastri S. Global strategies for cervical cancer prevention. Curr Opin Obstet Gynecol. 2016;28:4–10.
   PubMed Web of Science ®Google Scholar
• Conway MJ, Meyers C. Replication and assembly of human papillomaviruses. J Dent Res. 2009;88:307–317.
   PubMed Web of Science ®Google Scholar
• Dochez C, Bogers JJ, Verhelst R, et al. HPV vaccines to prevent cervical cancer and genital warts: an update. Vaccine. 2014;32:1595–1601.
   PubMed Web of Science ®Google Scholar
• Zsemlye M. High-grade cervical dysplasia: pathophysiology, diagnosis, and treatment. Obstet Gynecol Clin North Am. 2008;35:615-21; ix.
   PubMed Web of Science ®Google Scholar
• Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105:103–104.
   PubMed Web of Science ®Google Scholar
• Salicru SR, de la Torre JF, Gil-Moreno A. The surgical management of early-stage cervical cancer. Curr Opin Obstet Gynecol. 2013;25:312–319.
   PubMed Web of Science ®Google Scholar
• Li H, Wu X, Cheng X. Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol. 2016;27:e43.
   PubMed Web of Science ®Google Scholar
• Bizzarri N, Ghirardi V, Alessandri F, et al. Bevacizumab for the treatment of cervical cancer. Expert Opin Biol Ther. 2016;16:407–419.
   PubMed Web of Science ®Google Scholar
• Kokka F, Bryant A, Brockbank E, et al. Surgical treatment of stage IA2 cervical cancer. Cochrane Database Syst Rev. 2014;(5):Cd010870. DOI:10.1002/14651858.CD010870.pub2
   PubMed Web of Science ®Google Scholar
• Rydzewska L, Tierney J, Vale CL, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev. 2012;12:Cd007406.
   PubMed Web of Science ®Google Scholar
• Al-Mansour Z, Verschraegen C. Locally advanced cervical cancer: what is the standard of care? Curr Opin Oncol. 2010;22:503–512.
   PubMed Web of Science ®Google Scholar
• Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144–1153.
   PubMed Web of Science ®Google Scholar
• Neoadjuvant Chemotherapy for Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer. 2003;39:2470–2486.
   PubMed Web of Science ®Google Scholar
• Thigpen T, Shingleton H, Homesley H, et al. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer. 1981;48:899–903.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649–4655.
   PubMed Web of Science ®Google Scholar
• Kitagawa R, Katsumata N, Shibata T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol. 2015;33:2129–2135.
   PubMed Web of Science ®Google Scholar
• Zighelboim I, Wright JD, Gao F, et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol. 2013;130:64–68.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2009;27:1069–1074.
   PubMed Web of Science ®Google Scholar
• Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370:734–743.
   PubMed Web of Science ®Google Scholar
• Hertlein L, Lenhard M, Kirschenhofer A, et al. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients. Arch Gynecol Obstet. 2011;283:109–113.
   PubMed Web of Science ®Google Scholar
• Santin AD, Sill MW, McMeekin DS, et al. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;122:495–500.
   PubMed Web of Science ®Google Scholar
• Farley J, Sill MW, Birrer M, et al. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;121:303–308.
   PubMed Web of Science ®Google Scholar
• Kurtz JE, Hardy-Bessard AC, Deslandres M, et al. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial. Gynecol Oncol. 2009;113:16–20.
   PubMed Web of Science ®Google Scholar
• MITO (Multicentre Italian Trials in Ovarian cancer): CERV 2 trialâ ”A randomized phase II study of carboplatin and paclitaxel ± cetuximab, in advanced and/or recurrent cervical cancer. |2015 ASCO Annual Meeting |Abstracts |Meeting Library; 2015. Available from: http://meetinglibrary.asco.org/content/151507-156
   Google Scholar
• Blohmer J, Gore M, Kuemmel S, et al. Phase II study to determine response rate, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of treatment with the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 (matuzumab) in patients with recurrent cervical cancer. Proc Am Clin Onc. 2005;A2534.
   Google Scholar
• Cetina L, Crombet T, Jimenez-Lima R, et al. A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer. Cancer Biol Ther. 2015;16:684–689.
   PubMed Web of Science ®Google Scholar
• Goncalves A, Fabbro M, Lhomme C, et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol. 2008;108:42–46.
   PubMed Web of Science ®Google Scholar
• Sharma DN, Rath GK, Julka PK, et al. Role of gefitinib in patients with recurrent or metastatic cervical carcinoma ineligible or refractory to systemic chemotherapy: first study from Asia. Int J Gynecol Cancer. 2013;23:705–709.
   PubMed Web of Science ®Google Scholar
• Schilder RJ, Sill MW, Lee Y-C, et al. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2009;19:929–933.
   PubMed Web of Science ®Google Scholar
• Nogueira-Rodrigues A, Do Carmo CC, Viegas C, et al. Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer. Clin Cancer Res. 2008;14:6324–6329.
   PubMed Web of Science ®Google Scholar
• Nogueira-Rodrigues A, Moralez G, Grazziotin R, et al. Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer. Cancer. 2014;120:1187–1193.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Mas Lopez L, Zarba JJ, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010;28:3562–3569.
   PubMed Web of Science ®Google Scholar
• Mackay HJ, Tinker A, Winquist E, et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol. 2010;116:163–167.
   PubMed Web of Science ®Google Scholar
• Candelaria M, Arias-Bonfill D, Chavez-Blanco A, et al. Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha. Int J Gynecol Cancer. 2009;19:1632–1637.
   PubMed Web of Science ®Google Scholar
• Milosevic MF, Townsley CA, Chaudary N, et al. Sorafenib increases tumor hypoxia in cervical cancer patients treated with radiation therapy: results of a phase 1 clinical study. Int J Radiat Oncol Biol Phys. 2016;94:111–117.
   PubMed Web of Science ®Google Scholar
• Symonds RP, Gourley C, Davidson S, et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2015;16:1515–1524.
   PubMed Web of Science ®Google Scholar
• A phases II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology/Gynecologic Oncology Group study. |2015 ASCO Annual Meeting |Abstracts |Meeting Library; 2015. Available from: http://meetinglibrary.asco.org/content/152302-156
   Google Scholar
• Kudelka AP, Levy T, Verschraegen CF, et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res. 1997;3:1501–1505.
   PubMed Web of Science ®Google Scholar
• Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol. 2010;117:473–476.
   PubMed Web of Science ®Google Scholar
• Tinker AV, Ellard S, Welch S, et al. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecol Oncol. 2013;130:269–274.
   PubMed Web of Science ®Google Scholar
• De Melo AC, Grazziotin-Reisner R, Erlich F, et al. A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I. Cancer Chemother Pharmacol. 2016;78:101–109.
   PubMed Web of Science ®Google Scholar
• Kunos C, Deng W, Dawson D, et al. A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study. Int J Gynecol Cancer. 2015;25:484–492.
   PubMed Web of Science ®Google Scholar
• A limited access phase I trial of paclitaxel, cisplatin and ABT-888 in the treatment of advanced, persistent, or recurrent carcinoma of the cervix: an NRG/GOG study. |2015 ASCO Annual Meeting |Abstracts |Meeting Library; 2016. Available from: http://meetinglibrary.asco.org/content/148460-156
   Google Scholar
• Pohlmann P, DiLeone LP, Cancella AI, et al. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol. 2002;25:496–501.
   PubMed Web of Science ®Google Scholar
• Candelaria M, Cetina L, Perez-Cardenas E, et al. Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer. Eur J Gynaecol Oncol. 2010;31:386–391.
   PubMed Web of Science ®Google Scholar
• Candelaria M, Gallardo-Rincon D, Arce C, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol. 2007;18:1529–1538.
   PubMed Web of Science ®Google Scholar
• Coronel J, Cetina L, Pacheco I, et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol. 2011;28 Suppl 1:S540–S546.
   PubMed Web of Science ®Google Scholar
• Herrera FG, Chan P, Doll C, et al. A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment. Int J Radiat Oncol Biol Phys. 2007;67:97–103.
   PubMed Web of Science ®Google Scholar
• Gaffney DK, Winter K, Dicker AP, et al. A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. Int J Radiat Oncol Biol Phys. 2007;67:104–109.
   PubMed Web of Science ®Google Scholar
• Recombinant adenovirus-p53 combined with chemotherapy in treatment of locally advanced cervical cancer (a phase II study). |2013 ASCO Annual Meeting |Abstracts |Meeting Library; 2013. Available from: http://meetinglibrary.asco.org/content/110191-132
   Google Scholar
• Su X, Chen WJ, Xiao SW, et al. Effect and safety of recombinant Adenovirus-p53 transfer combined with radiotherapy on long-term survival of locally advanced cervical cancer. Hum Gene Ther. 2016;27(12):1008-1014. [Epub 2016 Aug 30]. DOI:10.1089/hum.2016.043.
   Web of Science ®Google Scholar
• Kersemaekers AM, Fleuren GJ, Kenter GG, et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res. 1999;5:577–586.
   PubMed Web of Science ®Google Scholar
• Soonthornthum T, Arias-Pulido H, Joste N, et al. Epidermal growth factor receptor as a biomarker for cervical cancer. Ann Oncol. 2011;22:2166–2178.
   PubMed Web of Science ®Google Scholar
• MITO (Multicentre Italian Trials in Ovarian cancer): CERV 2 trialâ ”A randomized phase II study of carboplatin and paclitaxel +/- cetuximab, in advanced and/or recurrent cervical cancer. |2015 ASCO Annual Meeting |Abstracts |Meeting Library; 2016. Available from: http://meetinglibrary.asco.org/content/151507-156
   Google Scholar
• Lopez-Ocejo O, Viloria-Petit A, Bequet-Romero M, et al. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene. 2000;19:4611–4620.
   PubMed Web of Science ®Google Scholar
• Cheng WF, Chen CA, Lee CN, et al. Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstet Gynecol. 2000;96:721–726.
   PubMed Web of Science ®Google Scholar
• Chen W, Li F, Mead L, et al. Human papillomavirus causes an angiogenic switch in keratinocytes which is sufficient to alter endothelial cell behavior. Virology. 2007;367:168–174.
   PubMed Web of Science ®Google Scholar
• Ji J, Zheng P-S. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells. Gynecol Oncol. 2010;117:103–108.
   PubMed Web of Science ®Google Scholar
• Ojesina AI, Lichtenstein L, Freeman SS, et al. Landscape of genomic alterations in cervical carcinomas. Nature. 2014;506:371–375.
   PubMed Web of Science ®Google Scholar
• Kim M-K, Kim T-J, Sung CO, et al. High expression of mTOR is associated with radiation resistance in cervical cancer. J Gynecol Oncol. 2010;21:181–185.
   PubMed Web of Science ®Google Scholar
• Husseinzadeh N, Husseinzadeh HD. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review. Gynecol Oncol. 2014;133:375–381.
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Alp E, Onen HI, et al. Reduced BCL2 and CCND1 mRNA expression in human cervical cancer HeLa cells treated with a combination of everolimus and paclitaxel. Contemp Oncol. 2016;20:28–32.
   Google Scholar
• Janku F, Wheler JJ, Westin SN, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012;30:777–782.
   PubMed Web of Science ®Google Scholar
• Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10:293–301.
   PubMed Web of Science ®Google Scholar
• Boulton S, Kyle S, Durkacz BW. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis. 1999;20:199–203.
   PubMed Web of Science ®Google Scholar
• Reinbolt RE, Hays JL. The role of PARP inhibitors in the treatment of gynecologic malignancies. Front Oncol. 2013;3:237.
   PubMedGoogle Scholar
• Michels J, Vitale I, Galluzzi L, et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res. 2013;73:2271–2280.
   PubMed Web of Science ®Google Scholar
• A limited access phase I trial of paclitaxel, cisplatin and ABT-888 in the treatment of advanced, persistent, or recurrent carcinoma of the cervix: an NRG/GOG study. |2015 ASCO Annual Meeting |Abstracts |Meeting Library; 2015. Available from: http://meetinglibrary.asco.org/content/148460-156
   Google Scholar
• Robertson KD. DNA methylation and human disease. Nat Rev Genet. 2005;6:597–610.
   PubMed Web of Science ®Google Scholar
• Kim YI, Giuliano A, Hatch KD, et al. Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma. Cancer. 1994;74:893–899.
   Google Scholar
• Yang H-J. Aberrant DNA methylation in cervical Carcinogenesis. Chin J Cancer. 2013;32:42–48.
   PubMed Web of Science ®Google Scholar
• Bhat S, Kabekkodu SP, Noronha A, et al. Biological implications and therapeutic significance of DNA methylation regulated genes in cervical cancer. Biochimie. 2016;121:298–311.
   PubMed Web of Science ®Google Scholar
• Takai N, Kira N, Ishii T, et al. Novel chemotherapy using histone deacetylase inhibitors in cervical cancer. Apjcp. 2011;12:575–580.
   Google Scholar
• Ozören N, El-Deiry WS. Cell surface Death Receptor signaling in normal and cancer cells. Semin Cancer Biol. 2003;13:135–147.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867.
   PubMed Web of Science ®Google Scholar
• Gaffney DK, Holden J, Davis M, et al. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2001;49:1213–1217.
   PubMed Web of Science ®Google Scholar
• Hoellen F, Waldmann A, Banz-Jansen C, et al. Expression of cyclooxygenase-2 in cervical cancer is associated with lymphovascular invasion. Oncol Lett. 2016;12:2351–2356.
   PubMed Web of Science ®Google Scholar
• Raju U, Nakata E, Yang P, et al. In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. Int J Radiat Oncol Biol Phys. 2002;54:886–894.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23:363–398.
   PubMed Web of Science ®Google Scholar
• A prospective study to evaluate the efficacy of curcumin in the management of advanced carcinoma cervix. |2010 ASCO Annual Meeting |Abstracts |Meeting Library; 2010. Available from: http://meetinglibrary.asco.org/content/54003-74
   Google Scholar
• Hu YY, Zheng MH, Zhang R, et al. Notch signaling pathway and cancer metastasis. Adv Exp Med Biol. 2012;727:186–198.
   PubMed Web of Science ®Google Scholar
• Pant S, Jones SF, Kurkjian CD, et al. A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer. Eur J Cancer. 2016;56:1–9.
   PubMed Web of Science ®Google Scholar
• Dixon H, Norbury CJ. Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function. Cell Cycle. 2002;1:362–368.
   PubMed Web of Science ®Google Scholar
• Hirai H, Arai T, Okada M, et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther. 2010;9:514–522.
   PubMed Web of Science ®Google Scholar
• Wang Y, Decker SJ, Sebolt-Leopold J. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther. 2004;3:305–313.
   PubMed Web of Science ®Google Scholar
• Koga F, Kihara K, Neckers L. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res. 2009;29:797–807.
   PubMed Web of Science ®Google Scholar
• Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005;10:86–103.
   PubMed Web of Science ®Google Scholar
• Bisht KS, Bradbury CM, Mattson D, et al. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res. 2003;63:8984–8995.
   PubMed Web of Science ®Google Scholar
• Katsumata N, Hirai Y, Kamiura S, et al. Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer. Ann Oncol. 2011;22:1353–1357.
   PubMed Web of Science ®Google Scholar
• Yunokawa M, Katsumata N, Yamamoto H, et al. A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer. Cancer Chemother Pharmacol. 2013;71:1369–1374.
   PubMed Web of Science ®Google Scholar
• Benjapibal M, Thirapakawong C, Leelaphatanadit C, et al. A pilot phase II study of capecitabine plus cisplatin in the treatment of recurrent carcinoma of the uterine cervix. Oncology. 2007;72:33–38.
   PubMed Web of Science ®Google Scholar
• Errihani H, M’Rabti H, Ismaili N, et al. Phase II trial of capecitabine and cisplatin in advanced, persistent, or recurrent carcinoma of the cervix. Int J Gynecol Cancer. 2011;21:373–377.
   PubMed Web of Science ®Google Scholar
• Goedhals L, Van Wiyk AL, Smith BL, et al. Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial. Int J Gynecol Cancer. 2006;16:1172–1178.
   PubMed Web of Science ®Google Scholar
• Lorusso D, Ferrandina G, Pignata S, et al. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol. 2010;21:61–66.
   PubMed Web of Science ®Google Scholar
• Miller DS, Blessing JA, Bodurka DC, et al. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2008;110:65–70.
   PubMed Web of Science ®Google Scholar
• Alberts DS, Blessing JA, Landrum LM, et al. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. Gynecol Oncol. 2012;127:451–455.
   PubMed Web of Science ®Google Scholar
• Kunos CA, Radivoyevitch T, Pink J, et al. Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers. Radiat Res. 2010;174:574–581.
   PubMed Web of Science ®Google Scholar
• Kunos CA, Waggoner S, Von Gruenigen V, et al. Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer. Clin Cancer Res. 2010;16:1298–1306.
   PubMed Web of Science ®Google Scholar
• Kunos CA, Sherertz TM. Long-term disease control with triapine-based radiochemotherapy for patients with stage IB2-IIIB cervical cancer. Front Oncol. 2014;4:184.
   PubMedGoogle Scholar
• Bryan JT, Buckland B, Hammond J, et al. Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine. Curr Opin Chem Biol. 2016;32:34–47.
   PubMed Web of Science ®Google Scholar
• Abdulkarim B, Sabri S, Deutsch E, et al. Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene. 2002;21:2334–2346.
   PubMed Web of Science ®Google Scholar
• Deutsch E, Haie-Meder C, Bayar MA, et al. Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients. Oncotarget. 2016;7:25549–25557.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Yang A, Wu TC, et al. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. J Gynecol Oncol. 2016;27:e51.
   PubMed Web of Science ®Google Scholar
• Petit BP. ADXS11-001 immunotherapy targeting HPV-E7: updated survival and safety data from a phase 2 study in Indian women with recurrent/refractory cervical cancer. J Immunother Cancer. 2013;1(Suppl 1):P231. DOI:10.1186/2051-1426-1-S1-P231.
   PubMedGoogle Scholar
• Mohanty S, Huang J, Basu A. Enhancement of cisplatin sensitivity of cisplatin-resistant human cervical carcinoma cells by bryostatin 1. Clin Cancer Res. 2005;11:6730–6737.
   PubMed Web of Science ®Google Scholar
• Nezhat F, Wadler S, Muggia F, et al. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study. Gynecol Oncol. 2004;93:144–148.
   PubMed Web of Science ®Google Scholar
• Stevanovic S, Draper LM, Langhan MM, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33:1543–1550.
   PubMed Web of Science ®Google Scholar
• Pembrolizumab in patients with advanced cervical squamous cell cancer: preliminary results from the phase Ib KEYNOTE-028 study. |2016 ASCO Annual Meeting |Abstracts |Meeting Library; 2016. Available from: http://meetinglibrary.asco.org/content/167980-176
   Google Scholar
• Falchook GS, Leidner R, Stankevich E, et al. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer. 2016;4:70.
   PubMed Web of Science ®Google Scholar
• Van der Burg SH, Arens R, Ossendorp F, et al. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer. 2016;16:219–233.
   PubMed Web of Science ®Google Scholar